Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test.
From lab bench to bedside, and back again
UCL was selected as the hub of the UK DRI in 2016 because of its strength to bring together excellent clinical and basic neuroscience research to advance our understanding of neurodegeneration and identify novel targets and therapeutic approaches for dementia. As the hub, it has a larger research programme and also is the location for the national headquarters team who connect the whole institute together.
Research at the UK DRI at UCL covers the journey from the person living with dementia to the laboratory and back again - with improved diagnosis and potential therapies put to the test. The groups believe in intervening earlier in disease in order to change the trajectory.
We need to better understand the diversity and complexity of neurodegenerative diseases, like Alzheimer's disease, in order to understand the mechanisms involved, and ultimately how we can alter them to improve people's lives.
We must find treatments quicker, and that's why the UK DRI at UCL is taking a novel approach by integrating diverse expertise for efficiency, from genetics to diagnostics.
This work is enhanced by incredible clinical resources. Researchers have access to unique clinical cohorts, where comprehensive data has been collected throughout disease progression including memory assessments and brain tissue. The UK DRI at UCL provides a clinical arm to the whole of the UK DRI.
The future iconic home of the UK DRI at UCL will be alongside UCL's Queen Square Institute of Neurology in a new building on Gray's Inn Road.
Visit the UK DRI at UCL local website for up-to-date news.
The UK DRI at UCL is offering an exciting opportunity to join the Bartels lab as a Research Technician. The Bartels lab specialises to fill the gap for scientific research on synuclein multimers and lipidomics associated with Parkinson’s Disease. The lab is dedicated to understanding the biochemical nature of α-synuclein in healthy and diseased patients. The postholder will provide experimental support for the research project, which will comprise of the analysis of human postmortem brain material and various cell culture models including iPSC-derived and primary human neurons as well as structural in vitro assays using recombinant protein. The native brain tissue and the in vitro models will be used to study α-synuclein multimers and lipid composition in different Synucleinopathies. In vitro, aggregation assays, electron microscopy, CD spectroscopy, and FCS will be used to elucidate context-dependent folding. Technical assistance is required with histopathology techniques, biochemical analysis such as crosslinking and Western Blot, RNA and DNA analysis and cell culture, as well as protein expression and purification. Ref: B02-06769, Closing date: Thursday 25 April 2024
Apply to centre